5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy  by Navari, Rudolph M.
Biochimica et Biophysica Acta 1848 (2015) 2738–2746
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbamem5-HT3 receptors as important mediators of nausea and vomiting due
to chemotherapy☆,☆☆Rudolph M. Navari ⁎
Cancer Care Program, Eastern Europe, World Health Organization
Indiana University School of Medicine South Bend, USA
South Bend Medical Services Corporation, USA☆ This article is part of a Special Issue entitled:Membra
cancers.
☆☆ The author has no conﬂicts of interest and there are
manuscript.
⁎ 202 Lincolnway East, Suite #105, Mishawaka, IN 465
E-mail address: rmnavari@gmail.com.
http://dx.doi.org/10.1016/j.bbamem.2015.03.020
0005-2736/© 2015 Elsevier B.V. All rights reserved.a b s t r a c ta r t i c l e i n f oArticle history:
Received 18 July 2014
Received in revised form 26 February 2015
Accepted 20 March 2015
Available online 30 March 2015
Keywords:
5-HT3 receptor antagonists
Serotonin
Chemotherapy-induced nausea and vomiting
AntiemeticsChemotherapy-induced nausea and vomiting (CINV) is associated with a signiﬁcant deterioration in quality of
life. The emetogenicity of the chemotherapeutic agents, repeated chemotherapy cycles, and patient risk factors
signiﬁcantly inﬂuence CINV. The use of a combination of a 5-hydroxytryptamine-3 (5-HT3) receptor antagonist,
dexamethasone, and a neurokinin-1 (NK-1) receptor antagonist has signiﬁcantly improved the control of acute
and delayed emesis in single-day chemotherapy. The ﬁrst generation 5-HT3 receptor antagonists have been
very effective in the control of chemotherapy induced emesis in the ﬁrst 24 h postchemotherapy (acute emesis),
but have not been as effective against delayed emesis (24–120 h postchemotherapy). Palonosetron, a second
generation 5-HT3 receptor antagonistwith a different half-life, a different binding capacity, and a differentmech-
anism of action than the ﬁrst generation 5-HT3 receptor antagonists appears to be the most effective agent in its
class. Despite the control of emesis, nausea has not been well controlled by current agents. Olanzapine, a FDA
approved antipsychotic that blocks multiple neurotransmitters: dopamine at D1, D2, D3, D4 brain receptors,
serotonin at 5-HT2a, 5-HT2c, 5-HT3, 5-HT6 receptors, catecholamines at alpha1 adrenergic receptors, acetylcholine
at muscarinic receptors, and histamine at H1 receptors, has emerged in recent trials as an effective preventative
agent for chemotherapy–induced emesis and nausea, as well as a very effective agent for the treatment of break-
through emesis and nausea. This article is part of a Special Issue entitled:Membrane channels and transporters in
cancers.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Chemotherapy-induced nausea and vomiting (CINV) is associated
with a signiﬁcant deterioration in quality of life and is perceived by
patients as a major adverse effect of the treatment [1,2]. Increased risk
of CINV is associated with the type of chemotherapy administered
(Table 1) and speciﬁc patient characteristics (Table 2) [2]. CINV can re-
sult in serious complications such as weakness, weight loss, electrolyte
imbalance, dehydration, or anorexia and is associated with a variety of
complications, including fractures, esophageal tears, decline in behav-
ioral and mental status, and wound dehiscence [1,2]. Patients who are
dehydrated, debilitated, or malnourished, as well as those who have
an electrolyte imbalance or thosewhohave recently undergone surgery
or radiation therapy, are at greater risk of experiencing serious compli-
cations from CINV [1,2].ne channels and transporters in
no sources of funding for this
44, USA. Tel.: +1 574 252 7225.5-HT3 receptor antagonistswere discovered through the exploration
of the mechanism of high dose metoclopramide and the interactions
with 5-HT receptors [3].
The clinical introduction of 5-hydroxytryptamine-3 (5-HT3) recep-
tor antagonists resulted in a marked improvement in the prevention
of CINV in the ﬁrst 24 h post chemotherapy [2]. The addition of dexa-
methasone to a 5-HT3 receptor antagonist has further improved the
control of CINV [4]. Recent studies have demonstrated improvement
in the control of CINV in the period 24 h to 120 h postchemotherapy
with the use of three new agents, palonosetron, a second generation
5-HT3 receptor antagonist [2,4,5], aprepitant, the ﬁrst agent available
in the drug class of neurokinin-1 (NK-1) receptor antagonists [2,6],
and olanzapine, an antipsychotic which blocks multiple neurotransmit-
ters in the central nervous system [2,7–9].
The primary endpoint used for studies evaluating various agents for
the control of CINV has been complete response (no emesis, no use of
rescue medication) over the acute (24 h postchemotherapy), delayed
(24–120 h), and overall (0–120 h) periods [3]. Studies have shown
that the combination of a 5-HT3 receptor antagonist, dexamethasone,
and a NK-1 receptor antagonist have improved the control of emesis
in patients receiving either highly emetogenic chemotherapy (HEC) or
moderately emetogenic chemotherapy (MEC) over a 120 h period
Table 1
Emetic potential of chemotherapy agents.
Emetogenic
potential
Typical agents Deﬁnition (no CINV prevention)
High Cisplatin
Dacarbazine
Melphalan (high dose)
Nitrogen mustard
Cyclophosphamide plus
an Anthracycline
Emesis in nearly all patients
Moderate Anthracyclines
Carboplatin
Carmustine (high dose)
Cyclophosphamide
Ifosfamide
Irinotecan
Methotrexate (high dose)
Oxaliplatin
Emesis in 30–90% of patients
Low Etoposide
5-Fluorouracil
Gemcitabine
Mitoxantrone
Taxanes
Topotecan
Emesis in 10%–30% of patients
Minimal Bortezomib
Hormones
Vinblastine
Vinca alkaloids
Vinorelbine
Bleomycin
Emesis in b10% of patients
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studies have measured nausea as a secondary endpoint and have dem-
onstrated that nausea has not been well controlled [10].
Emesis is a well deﬁned event which is easily measured, but nausea
may be more subjective and more difﬁcult to measure. There are, how-
ever, two well deﬁned measures of nausea which appear to be effective
measurement tools which are reproducible: the Visual Analogue Scale
(VAS) and the Likert Scale [11]. The VAS is a scale from 0 to 10 or 0 to
100 with zero representing no nausea and 10 or 100 representing
maximal nausea. The Likert Scale asks patients to rate nausea as None,
Mild, Moderate or Severe.
Many studies have reported the secondary endpoint of “no signiﬁ-
cant nausea” or “only mild nausea” [3–6]. Studies that have reported
“no nausea”may be more useful in identifying the most effective avail-
able antinausea agents [7,9,10].
The introduction of more effective antiemetic agents has reduced
the level of emesis and nausea as signiﬁcant complications of chemo-
therapy. The purpose of this review is to deﬁne the role of the 5-HT3
receptors as important mediators of CINV. The use of these agents in
various clinical settings is described using the recently established
guidelines from the Multinational Association of Supportive Care in
Cancer (MASCC) and the European Society of Medical Oncology
(ESMO) [12], the American Society of Clinical Oncology (ASCO) [13]
and the National Comprehensive Cancer Network (NCCN) guidelines
[14]. The literature cited in the report consists of the primary clinical
trials used for the Food and Drug Administration (FDA) approval of
the various agents as well as recent comprehensive reviews.Table 2
Patient-related risk factors for emesis following chemotherapy.
Major factors Minor factors
Female History of motion sickness
Age b 50 years Emesis during past pregnancy
History of low prior chronic alcohol intake
(b1 oz of alcohol/day)
History of previous chemotherapy-induced emesis1.1. Pathophysiology of nausea and vomiting
The sensation of nausea and the act of vomiting are protective
reﬂexes that rid the intestine and stomach of toxic substances. The
experience of nausea is subjective, and nausea may be considered a
prodromal phase to the act of vomiting [11] although signiﬁcant nausea
may occur without vomiting. Vomiting consists of a pre-ejection phase,
retching, and ejection and is accompanied by shivering and salivation.
Vomiting is triggered when afferent impulses from the cerebral cortex,
chemoreceptor trigger zone (CTZ), pharynx, and vagal afferent ﬁbers
of the gastrointestinal (GI) tract travel to the vomiting center (VC), lo-
cated in the medulla (Fig. 1). Efferent impulses then travel from the
vomiting center to the abdominal muscles, salivation center, cranial
nerves, and respiratory center, causing vomiting. It is thought that che-
motherapeutic agents cause vomiting by activating neurotransmitter
receptors located in the CTZ, GI tract, and vomiting center.
The mechanisms of emesis are not well deﬁned, but investigations
suggest that emesismay be primarilymediated through neurotransmit-
ters (serotonin, dopamine, substance P, muscarinic) in the GI tract and
the central nervous system [11]. Fig. 1 shows that chemotherapy agents
may directly affect areas in the cerebral cortex, the medulla oblongata,
or may stimulate the small intestine of the GI tract via the vagus
nerve. A vomiting center (VC), termed the “central pattern generator”
by some authors [15], appears to be located in the lateral reticular for-
mation of the medulla, which coordinates the mechanism of nausea
and vomiting. An additional important area, also located in themedulla,
is the CTZ in the area postrema near the 4th ventricle [15]. It is strongly
suspected that the nucleus tractus solitarius (NTS) neurons lying ven-
trally to the area postrema initiate emesis [16]. This medullary area is
a convergence point for projections arising from the area postrema
and the vestibular and vagal afferents [16].
The NTS is a good candidate for the site of action of centrally acting
antiemetics. The main approach to the control of emesis has been to
identify the active neurotransmitters and their receptors in the central
nervous system and the GI tract that mediate the afferent inputs to
the VC (Fig. 2). Agents that may block these neurotransmitter receptors
in the CTZ, the VC, or the GI tractmay be useful in preventing or control-
ling emesis (Table 3).
Nausea is a difﬁcult-to-describe, sick or queasy sensation, usually
perceived as being in the stomach that is sometimes followed by emesis
[11]. The experience of nausea is difﬁcult to describe in another person.
Nausea and emesis are not necessarily on a continuum. One can experi-
ence nausea without emesis and one can have sudden emesis without
nausea. Nausea has been assumed to be the conscious awareness of
unusual sensations in the “vomiting center” of the brainstem (Fig. 1),
but the existence of such a center and its relationship to nausea remain
controversial [11].
The study of the receptors that are illustrated in Fig. 2 has guided the
development of the antagonists to the serotonin and the substance-P
receptors with relative success in controlling emesis. It is not clear
whether the serotonin and/or the substance P receptors are important
in the control of nausea. Other receptors such as dopaminergic,
histaminic and muscarinic may be the dominant receptors in the
control of nausea [3,7,10].
1.2. Types of CINV
Five categories are used to classify CINV: acute, delayed, anticipatory,
breakthrough, and refractory. Nausea and vomitingmay occur any time
after the administration of chemotherapy, but the mechanisms appear
different for CINV occurring in the ﬁrst 24 h after chemotherapy in
contrast to that which occurs in the period from day 2 to day 5 after
chemotherapy. In order to differentiate these mechanisms, the term
acute-onset CINV refers to nausea and/or vomiting occurring within
24 h of chemotherapy administration [3]. The incidence of acute emesis
and/or nausea reﬂects several treatment-related factors, including the
Fig. 1. Physiology of chemotherapy-induced emesis.
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of the chemotherapy, the dosage of the emetogenic agents, and patient-
related factors [3].
Nausea and/or vomiting that develop more than 24 h after chemo-
therapy administration is known as delayed emesis and/or nausea.
Typically occurring with administration of chemotherapy agent cisplatin,
doxorubicin, or cyclophosphamide, delayed emesis/nausea is more com-
mon in those who experience acute emesis/nausea.
Other predictive factors include the dose and the emetogenicity of
the chemotherapeutic agent, patient gender and age, and protectionNeurotransmitters in
Emetic ce
GABA
Dopamine
Substance P
Serotonin
Fig. 2. Neurotransmittersagainst nausea and vomiting in previous cycles of chemotherapy [1,2,
10]. For cisplatin, which has been most extensively studied, delayed
emesis reaches peak intensity 2–3 days subsequent to chemotherapy
administration and can last up to a week [1,12–14].
If patients experience CINV, they may develop a conditioned re-
sponse known as anticipatory nausea and/or vomiting which occurs
prior to the administration of chemotherapy in future chemotherapy
cycles and is attributed to the adverse memory of prior CINV. Incidence
rates for this type of nausea and vomiting range from 10–45%, with
nausea occurring more frequently [1,12–14].volved in emesis
nter
Histamine
Endorphins
Acetylcholine
involved in emesis.
Table 3
Antiemetic receptor antagonists.
Dopamine receptor antagonists 5-HT3 receptor antagonists Dopa-5-HT3 receptor antagonists NK-1 receptor antagonists
Butyrophenones
Olanzapine
Phenothiazines
Azasetron
Dolasetron (not recomendad for use per FDA)
Granisetron
Olanzapine
Ondansetron (intravenous dose restriction per FDA)
Palonosetron
Ramosetron
Tropisetron
Metoclopramide Aprepitant
Fosaprepitant
Table 4
Serotonin antagonists and dosage before chemotherapy.a
Antiemetic Route Dosage
Azasetron IV 10 mg
Dolasetron (not recommended
for use per FDA)
IV 100 mg or 1.8 mg/kg
PO 100 mg
Granisetron IV 10 μg/kg or 1 mg
PO 2 mg (or 1 mg twice daily)
Ondansetron IV 8 mg (restricted to b 16 mg)
PO 24 mg
Palonosetron IV 0.25 mg
PO 0.50 mg
Ramosetron IV 0.30 mg
Tropisetron IV or PO 5 mg
a The same doses are used for highly and moderately emetic chemotherapy.
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tic use of antiemetic agents or requires “rescue” is called breakthrough
emesis. Vomiting and/or nausea occurring after chemotherapy in subse-
quent chemotherapy cycles when antiemetic prophylaxis and/or rescue
have failed in earlier cycles is known as refractory emesis [1,12–14].
2. 5-HT3 receptor antagonists as antiemetic agents
2.1. Dopamine receptor antagonists
Dopamine receptors are known to exist in the CTZ, and this is the
main area of activity of the dopamine antagonists, such as the phenothi-
azines and the butyrophenones (droperidol, haloperidol). A high level
of blockade of thedopamine receptors, however, results in extrapyrami-
dal reactions, as well as disorientation and sedation, limiting the clinical
use of these agents. Their current use is primarily to treat established
nausea and emesis and not for CINV prophylaxis [14].
2.2. Serotonin (5-HT3) receptor antagonists
Serotonin receptors, speciﬁcally the 5-HT3 receptors, exist in the
central nervous system and in the GI tract. The 5-HT3 receptor antago-
nists appear to act through both the central nervous system and the GI
tract via the vagus and splanchnic nerves. The main toxicities of these
5-HT3 receptor antagonists consist only of a mild headache, occasional
diarrhea, and constipation [17].
The introduction of 5-HT3 receptor antagonists for the prevention of
chemotherapy-induced nausea and emesis, as well as post-operative
and radiotherapy-induced nausea and vomiting, has resulted in an
improvement in supportive care [17,18]. Treatment guidelines for the
prevention of CINV recommended by a number of international groups
[12–14] suggest the use of a 5-HT3 receptor antagonist and dexametha-
sone prechemotherapy for the prevention of acute CINV and the use of
dexamethasone following chemotherapy for the prevention of delayed
nausea and vomiting.
2.2.1. First generation serotonin (5-HT3) receptor antagonists
Table 4 shows the 5-HT3 receptor antagonists currently in use. The
ﬁrst generation serotonin (5-HT3) receptor antagonists, dolasetron
[17], granisetron [17], ondansetron [17], tropisetron [19], azasetron
[20] and ramosetron [21], are equivalent in efﬁcacy and toxicities
when used in the recommendeddoses and compete only on aneconom-
ic basis [3,17,22,23]. They have not been associated with major toxic-
ities, with the most commonly reported adverse events being mild
headache, constipation, and occasionallymild diarrhea [3,17]. Azasetron
and ramosetron are not available in North America and Europe and have
not been compared extensively to the other 5-HT3 receptor antagonists.
They aremarketed primarily in Southeast Asia. A prolongation of car-
diac conduction intervals has been reported for this class of compounds
with dolasetron being more extensively studied than granisetron and
ondansetron [23].
In 2006, Canada issued a drug alert for dolasetron, due to the poten-
tial of serious cardiovascular adverse events (cardiac arrhythmias) [24],stating that dolasetronwas not indicated for use in children, but only for
prevention of CINV in adults [24]. Subsequently, in 2010, the U.S. FDA
announced that the intravenous form of dolasetron should no longer
be used to prevent CINV in any patient. New data suggests that
dolasetron injection can increase the risk of developing a prolongation
of the QT interval which may potentially precipitate life threatening
ventricular arrhythmias [25,26].
In 2012, the FDA placed a restriction on the doses of intravenous
ondansetron due to the risk of prolongation of the QT interval [27].
Patients who may be at particular risk for QT prolongation with
ondansetron are those with congenital long QT syndrome, congestive
heart failure, bradyarrhythmias, or patients taking concomitantmedica-
tions that prolong the QT interval. The use of a single 32mg intravenous
dose of ondansetron should be avoided. New information indicates that
QT prolongation occurs in a dose–dependentmanner, and speciﬁcally at
a single intravenous dose of 32mg. The lower dose intravenous regimen
of 0.15mg/kg every 4 h for three dosesmay be used in adultswith CINV.
However, no single intravenous dose of ondansetron should exceed
16 mg due to the risk of QT prolongation. The new information does not
change any of the recommended oral dosing regimens for ondansetron,
including the single oral dose of 24 mg for CINV [27].
The ﬁrst generation 5-HT3 receptor antagonists have been very
effective in the control of chemotherapy induced emesis in the ﬁrst
24 h postchemotherapy (acute emesis), but have not been as effective
against delayed emesis (24–120 h postchemotherapy) [28–30]. The
ﬁrst generation 5-HT3 receptor antagonists alone do not add signiﬁcant
efﬁcacy to that obtained by dexamethasone in the control of delayed
emesis [29]. Hickok et al. [30] reported that the ﬁrst generation 5-HT3s
used in the delayed periodwere nomore effective than prochlorperazine
in controlling nausea. The antiemetic effects of prochlorperazine can be
attributed to postsynaptic dopamine receptor blockade in the CTZ. A
meta-analysis [29] showed that there was neither clinical evidence nor
considerations of cost effectiveness to justify using the ﬁrst generation
5-HT3 antagonists beyond 24 h after chemotherapy for the prevention
of delayed emesis. A number of studies have also demonstrated that
there has been poor control of delayed nausea by the ﬁrst generation
5-HT3 receptor antagonists in patients receiving MEC or HEC [8,10,31,
32]. The use of granisetron and dexamethasone in patients receiving
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ondansetron plus dexamethasone in patients receiving MEC resulted in
“no nausea” in 33% of patients and “no signiﬁcant nausea” in 56% of
patients [32].
2.2.2. Extended release transdermal granisetron (APF530)
Recently, a new formulation of a 5-HT3 receptor antagonist, trans-
dermal granisetron, has been developed, and approved by the FDA
[33]. Three Phase I studies have evaluated the pharmacology of the
transdermal delivery and have demonstrated that the plasma concen-
tration is similar to levels obtained by 2mg of oral granisetron adminis-
tered every day during the same time period [33]. A randomized,
double-blind, Phase III clinical trial evaluated the antiemetic efﬁcacy of
transdermal granisetron compared to oral granisetron in patients
receiving MEC and HEC [34]. There was no signiﬁcant difference in the
control of acute or delayed emesis between transdermal and oral
granisetron. The data demonstrated that transdermal granisetron was
effective and safe in the control of acute emesis induced by MEC and
HEC [34].
Raftopoulos et al. [35] reported that two doses (5 mg and 10 mg) of
sustained release granisetron (AFP530)were non-inferior to the second
generation 5-HT3 receptor antagonist palonosetron with respect to
complete response during the acute phase (24 h postchemotherapy)
in patients receiving MEC or HEC. The higher dose of APF530 (10 mg)
was non-inferior to palonosetron during the delayed phase (24–120 h
postchemotherapy) in patients receiving MEC.
2.2.3. Second generation serotonin (5-HT3) receptor
antagonists: palonosetron
Palonosetron is a second generation 5-HT3 receptor antagonist
which has antiemetic activity at both central and GI sites [4,5]. The
majority of evidence suggests that the GI site may be predominant
[36]. In comparison to the ﬁrst generation 5-HT3 receptor antagonists,
it has a higher potency, a signiﬁcantly longer half-life, and a different
molecular interaction with 5-HT3 receptors [4,5,37,38] (Table 5) and
may have some efﬁcacy in controlling delayed CINV compared to the
ﬁrst generation 5-HT3 receptor antagonists.
Palonosetron has demonstrated a 5-HT3 receptor binding afﬁnity at
least thirty-fold higher than other 5-HT3 receptor antagonists [4,5].
Rojas et al. [38] reported that palonosetron exhibited allosteric binding
andpositive cooperativitywhenbinding to the 5-HT3 receptor compared
to simple bimolecular binding for both granisetron and ondansetron.
Additional studies by Rojas et al. [38] suggested that palonosetron trig-
gers 5-HT3 receptor internalization and causes prolonged inhibition of
receptor function. Differences in binding and effects on receptor function
may explain some differences between palonosetron and the ﬁrst gener-
ation 5-HT3 receptor antagonists [4,5]. These differences may explain
palonosetron's efﬁcacy in delayed CINV compared to the ﬁrst generation
receptor antagonists [4,5].
Additional, in vitro studies [39–42] with NG108-15 cells have dem-
onstrated that in the absence of serotonin, palonosetron inhibited the
substance P mediated response while ondansetron and granisetron
had no effect. In the same system, Netupitant, a NK-1 receptor antago-
nist, also inhibited the substance P response as expected from a NK-1
receptor antagonist [40]. When both palonosetron and netupitant
were present, they exhibited an enhanced inhibition of the substanceTable 5
5-HT3 receptor antagonists' binding afﬁnity and plasma half-life.
Drug pKi [-log(Ki)] Half-life (hours)
Palonosetron 10.45 40
Ondansetron 8.39 4
Granisetron 8.91 9
Dolasetrona 7.60 7.3
a Half-life reported for hydrodolasetron, the active metabolite of dolasetron.P response compared to the two antagonists alone. It is speculated
that palonosetron may inhibit substance P medicated responses
through its unique interactions with the 5-HT3 receptor [41,42].
Phase III comparative studies suggest that the use of palonosetron
alone improves the complete response rate of acute and delayed emesis,
when compared with the use of the ﬁrst generation 5-HT3 receptor an-
tagonists alone in patients receiving MEC [43,44]. In patients receiving
HEC, palonosetron was as effective as ondansetron in the prevention
of acute CINV and with dexamethasone pre-treatment, palonosetron
was signiﬁcantly better than ondansetron in the overall 120-hour
post-treatment period [45].
In patients receiving HEC, palonosetron plus dexamethasone was
signiﬁcantly better than granisetron and dexamethasone in delayed
complete response and control of nausea, but there was a low number
of patients with no nausea with either regimen (no nausea, overall
period: 31.9% palonosetron group; 25.0% granisetron group) [31].
Two studies reported that palonosetron plus one day of dexametha-
sonewas as effective as palonosetron plus three days of dexamethasone
in the prevention of acute and delayed CINV in patients receiving MEC
[46,47]. There was also no difference in the control of nausea with the
addition of the additional days of dexamethasone. Boccia et al. recently
demonstrated that oral palonosetron had similar efﬁcacy and safety as
intravenous palonosetron for the prevention of acute CINV in patients
receiving MEC [48].
In a systematic review and meta-analysis of all randomized con-
trolled trials comparing a single dose of palonosetron with other 5-
HT3 receptor antagonists, Botrel et al. [49] concluded that palonosetron
was more effective than the ﬁrst generation receptor antagonists in
preventing acute and delayed CINV in patients receiving MEC or HEC,
regardless of the use of concomitant corticosteroids. Schwartzberg
et al. [50] concluded that palonosetron is more effective than the ﬁrst
generation 5-HT3 receptor antagonists in controlling CINV in thedelayed
and overall postchemotherapy periods based on a pooled analysis of
Phase III clinical studies of palonosetron versus ondansetron, dolasetron,
and granisetron. In a systemic review and meta-analysis of randomized
controlled trials, Popovic et al. [51] reported that palonosetron was safe
and more efﬁcacious than the other 5-HT3 receptor antagonists.
The safety and tolerability of palonosetron has been well document-
ed in multiple, large Phase III trials. There were no clinically relevant
differences seen among palonosetron, ondansetron, or dolasetron in
laboratory, electrocardiographic, or vital sign changes over multiple
cycles of chemotherapy [43–45,52,53]. The adverse reactions reported
were the most common reactions reported for the 5-HT3 receptor
antagonist drug class. There have been no reports of any adverse cardiac
events with palonosetron, speciﬁcally no prolongation of the QTc inter-
val in healthy volunteers or patients receiving repeated cycles of
emetogenic chemotherapy [4,5,52,53].
The published clinical studies on palonosetron have prompted the
NCCN guideline group to recommend palonosetron as the preferred
5-HT3 receptor antagonist for the prevention of acute nausea and
vomiting for patients receiving HEC [14]. and the ASCO [13], NCCN
[14], and MASCC [12] guideline groups to recommend palonosetron
for the prevention of acute and delayed nausea and vomiting for patients
receiving MEC.
There are no other second generation 5-HT3 receptor antagonists on
themarket and there is no information available on other second gener-
ation agents in development.2.3. Dopamine–serotonin receptor antagonists
Metoclopramide has antiemetic properties both in low doses as a
dopamine antagonist and in high doses as a serotonin antagonist. The
use of metoclopramide as a CINV preventative agent may be somewhat
efﬁcacious in relatively high doses (20 mg orally, four times/day) in the
delayed period [54], but may result in sedation and extrapyramidal side
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agent for CINV [17] as well as a treatment for breakthrough CINV [14].
2.4. Olanzapine
Olanzapine is a FDA approved antipsychotic that blocks multiple
neurotransmitters: dopamine at D1, D2, D3, D4 brain receptors, seroto-
nin at 5-HT2a, 5-HT2c, 5-HT3, 5-HT6 receptors, catecholamines at
alpha1 adrenergic receptors, acetylcholine at muscarinic receptors,
and histamine at H1 receptors [55,56]. Common side effects are seda-
tion and weight gain [57,58], as well as an association with the onset
of diabetes mellitus [59]. Sedation has been observed in some studies
with the doses (≤10 mg/day for 3 to 5 days) administered for the
prevention of CINV [7–9,60,61]. Weight gain and the onset of diabetes is
observed only when olanzapine is given at higher doses (N10 mg/day)
for longer time periods (daily for Nthree months) [57–59]. Olanzapine's
activity at multiple receptors, particularly at the D2, 5-HT2c, and 5-HT3
receptors which appear to be involved in nausea and emesis, suggests
that it may have signiﬁcant antiemetic properties.
A Phase I and a Phase II studydemonstrated that olanzapine could be
safely used for the prevention of acute and delayed emesis in cancer
patients receiving theirﬁrst cycle of chemotherapy [62,63]. These studies
concluded that olanzapine is safe andhighly effective in controlling acute
and delayed CINV in patients receiving MEC or HEC [63].
An additional Phase II trial demonstrated that olanzapine, when
combined with a single dose of dexamethasone and a single dose of
palonosetron, was very effective in controlling acute and delayed CINV
in patients receiving both HEC and MEC [64].
There was excellent control of nausea in 32 patients receiving MEC
(no nausea: overall period, 78%) without the use of multiple days of
dexamethasone.
A Phase III study showed the addition of olanzapine to the 5-HT3
receptor antagonist azasetron and dexamethasone improved delayed
CINV in patients receiving HEC or MEC [8]. There was a signiﬁcant im-
provement in nausea in the olanzapine group compared to the control
group of azasetron and dexamethasone for both patients receiving
HEC and MEC (Table 6).
An additional Phase III study randomized patients receiving HEC to
olanzapine, palonosetron, and dexamethasone (OPD) or aprepitant,
palonosetron, and dexamethasone (APD) for the prevention of CINV
[9]. The complete response was similar for the two groups, but no
nausea was signiﬁcantly improved in the OPD group (Table 6).
Mizukami et al. [61] reported a signiﬁcant improvement in emesis
and nausea postchemotherapy, and a signiﬁcant decrease in the use ofTable 6
Phase II and III trials of various agents for the treatment of chemotherapy induced nausea.
Ond: ondansetron; Palo: palonosetron; Dex: dexamethasone; Gran: granisetron; Cyclo: cyclophosp
OPD: olanzapine, palonosetron, dexamethasone; OAD: olanzapine, azasetron, dexamethasone
dexamethaone (*p b 0.01).
Study Chemotherapy Phase II or III No. ofpatients
Saito et al. [31] HEC III 1114
Navari et al. [9] HEC III 257
Warr et al. [32] Cyclo + Doxo/Epi III 866
Mizukami et al. [61] HEC, MEC III 44
Celio et al. [47] MEC III 334
Aapro et al. [46] Cyclo + Doxo/Epi III 300
Navari et al. [64] MEC II 32
Tan et al. [8] MEC
HEC
III
III
229
⁎ p value which is described in T6L5.rescuemedicationswhen olanzapinewas added to a 5-HT3 receptor an-
tagonist, a corticosteroid, and a NK-1 receptor antagonist in patients re-
ceiving MEC or HEC (Table 6).
A recent study has compared olanzapine to metoclopramide for the
treatment of breakthrough emesis and nausea in patients receiving HEC
and guideline directed antiemetic prophylaxis. Olanzapine was signiﬁ-
cantly better than metoclopramide for the treatment of breakthrough
emesis and nausea. This was the ﬁrst Phase III study on the treatment
of breakthrough emesis and nausea [65].
3. Role of the 5-HT3 receptor antagonists in themanagement of CINV
3.1. Principles in the management of CINV
Antiemetic guidelines have been published by the National Compre-
hensive Cancer Network (NCCN) [14], the American Society of Clinical
Oncology (ASCO) [13] and the Multinational Association of Supportive
Care in Cancer (MASCC) [12]. These guidelines form the basis for the
recommendations for the management of CINV. As new information
and new studies emerge, the guidelines will evolve to provide the
highest quality evidence based clinical practice.
3.1.1. Single-day chemotherapy
For patients receiving HEC, current evidence suggests the following
[12–14]:
• Prechemotherapy—Any of the 5-HT3 receptor antagonists with dexa-
methasone and a NK-1 receptor antagonist. The guidelines suggest
that the combination of cyclophosphamide and doxorubicin should
be considered as HEC and the appropriate preventative agents should
be used.
• Postchemotherapy—A NK-1 receptor antagonist and dexamethasone
on days 2–4.
For patients receiving MEC, current evidence suggests the following
[12–14]:
• Prechemotherapy—The 5-HT3 receptor antagonist palonosetron plus
dexamethasone. If palonosetron is not available, ondansetron or
granisetron may be employed.
• Postchemotherapy—Dexamethasone on days 2–4.
Antiemetic guidelines of the past [66] have included the available
oral ﬁrst generation 5-HT3 receptor antagonists as optional therapy forhamide; Doxo: doxorubicin; Epi: epirubicin APD: aprepitant, palonosetron, dexamethasone;
; AD: azasetron, dexamethasone; Dex1: one day of dexamethasone; Dex3: three days of
No nausea, delayed (%) No nausea, overall (%)
Palo + Dex: 38*
Gran + Dex: 27
Palo + Dex: 32*
Gran + Dex: 25
OPD: 69*
APD: 38
OPD: 69*
APD: 38
Ond + Dex: 36 Ond + Dex: 33
OLN + 5-HT3, Dex, Aprepitant 64*
5-HT3, Dex, Aprepitant 23
OLN + 5-HT3, Dex, Aprepitant 59*
5-HT3, Dex, Aprepitant 23
Palo + Dex1: 57
Palo + Dex3: 62
Palo + Dex1: 52
Palo + Dex3: 57
Palo + Dex1: 50
Palo + Dex3: 55
Palo + Dex1: 47
Palo + Dex3: 50
OPD: 78 OPD: 78
OAD: 83*
AD: 58
OAD: 70*
AD: 30
OAD: 83*
AD: 56
OAD: 70*
AD: 28
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this practice is low [17,29,30]. The ﬁrst generation 5-HT3 receptor
antagonists are no longer recommended for use postchemotherapy
[12–14].
For patients receiving low emetogenic chemotherapy, a single
agent in the form of a 5-HT3 receptor antagonist, dexamethasone,
or a phenothiazine, depending on the clinical situation, should be
used prechemotherapy, and an antiemetic following chemotherapy
should be given only as needed.
3.1.2. Treatment of breakthrough CINV
A phenothiazine, metoclopramide, dexamethasone, or olanzapine
may be effective in the treatment of breakthrough nausea and vomiting
[14]. A 5-HT3 receptor antagonist may also be effective unless a patient
presents with nausea and vomiting which developed following the use
of a 5-HT3 receptor antagonist as prophylaxis for chemotherapy or
radiotherapy-induced emesis. It is very unlikely that breakthrough
nausea and vomiting will respond to an agent in the same drug class
after unsuccessful prophylaxis with an agentwith the samemechanism
of action.
Patientswhodevelopnausea or vomitingpostchemotherapy (days 1
to 5) despite adequate prophylaxis should be considered for treatment
with a three-day regimen of oral olanzapine or oral metoclopramide.
A recently completed Phase III study demonstrated that oral olanzapine
(10 mg/day for three days) was signiﬁcantly better than oral
metoclopramide (10 mg TID for three days) in controlling both emesis
and nausea in patients receiving HEC who developed breakthrough
CINV despite guideline directed prophylactic antiemetics [65].
3.1.3. Refractory CINV
Patients who develop CINV during subsequent cycles of chemother-
apy when antiemetic prophylaxis has not been successful in controlling
CINV in earlier cycles should be considered for a change in the prophy-
lactic antiemetic regimen. If anxiety is considered to be a major patient
factor in the CINV, a benzodiazepine such as lorazepam or aprazolam
can be added to the prophylactic regimen. If the patient is receiving
HEC, olanzapine (days 1 to 3) can be substituted for aprepitant or
fosaprepitant in the prophylactic antiemetic regimen [9]. If the patient
is receiving MEC, aprepitant or fosaprepitant can be added to the
palonosetron and dexamethasone antiemetic regimen [67].
3.1.4. Anticipatory CINV
In order to prevent the occurrence of anticipatory CINV, patients
should be counseled prior to the initial course of treatment concerning
their “expectations” of CINV. Patients should be informed that very
effective prophylactic antiemetic regimens will be used and that 70–
75% of patients will have a complete response. The most effective pro-
phylactic antiemetic regimen for the patient's speciﬁc type of chemo-
therapy should be used prior to the ﬁrst course of chemotherapy in
order to obtain the optimum control of CINV during the ﬁrst course of
chemotherapy. If CINV is effectively controlled during the ﬁrst cycle, it
is likely that the patient will have effective control during subsequent
cycles of the same chemotherapy. If the patient has a poor experience
with CINV in the ﬁrst cycle, it may be more difﬁcult to control CINV in
subsequent cycles, and refractory and/or anticipatory CINV may occur.
The use of anti-anxiety medications such as lorazepam or another
benzodiazepine may be considered for excess anxiety prior to the ﬁrst
course of chemotherapy in order to obtain an optimum outcome and
prevent anticipatory CINV. If anticipatory CINV occurs despite the use
of prophylactic antiemetics, behavioral therapy might be considered.
3.1.5. Prevention and treatment of nausea
The current data in the literature frommultiple large studies suggest
that the ﬁrst or second generation 5-HT3 receptor antagonists have not
been effective in the control of nausea in patients receiving either MEC
or HEC, despite the marked improvement in the control of emesis withthese agents [10]. It appears that the serotonin 5-HT3 receptor may not
be of major importance inmediating nausea. Phase II and Phase III stud-
ies with olanzapine have demonstrated very good control of both eme-
sis and nausea in patients receiving either MEC or HEC [7–9,60]. As
previously stated, it is known that olanzapine blocks multiple neuro-
transmitters: dopamine at D1, D2, D3, D4 brain receptors, serotonin at
5-HT2a, 5-HT2c, 5-HT3, 5-HT6 receptors, catecholamines at alpha1 adren-
ergic receptors, acetylcholine at muscarinic receptors, and histamine at
H1 receptors [55,56]. There are no current deﬁnitive animal or human
data which point to which of these receptors may be more important
in controlling chemotherapy induced nausea. The 5-HT2C receptor
has been associated with weight gain [68], and this receptor may be
involved in the control of nausea.
At this time, olanzapine appears to have high potential for the pre-
vention of both emesis and nausea in patients receiving MEC or HEC
[7–9,60,61]. If patients are having difﬁcultywith signiﬁcant nausea, con-
sideration should be given to including olanzapine in their prophylactic
antiemetic regimen.Olanzapinemay also be efﬁcacious in the treatment
of breakthrough nausea [65].
4. Conclusions and future directions
The ﬁrst generation 5-HT3 receptor antagonists (dolasetron,
granisetron, ondansetron, tropisetron, ramosetron, and azasetron)
have signiﬁcant and similar efﬁcacy in the prevention of acute CINV
for patients receivingMEC orHEC. However, these agents do not appear
to have signiﬁcant efﬁcacy in the prevention of delayed CINV, and these
5-HT3 agents compete primarily on an economic basis.
The second generation 5-HT3 receptor antagonist palonosetron im-
proves the complete response rate of acute and delayed emesis in pa-
tients receiving MEC and HEC. The current data in the literature of
multiple large studies suggest that neither the ﬁrst or second generation
5-HT3 receptor antagonists have been effective in the control of nausea
in patients receiving either MEC or HEC, despite the marked improve-
ment in the control of emesis.
Phase II and Phase III clinical trials have demonstrated that the use of
olanzapine in combination with a 5-HT3 receptor antagonist and dexa-
methasone is safe and effective in the prevention of emesis and nausea
in patients receivingMEC or HEC. Further data from randomized studies
are needed to conﬁrm the efﬁcacy and safety of olanzapine in the pre-
vention of CINV in patients receiving MEC and HEC.
Olanzapine may be an important agent in the control of
chemotherapy-induced nausea. Olanzapine is known to affect a wide
variety of receptors including dopamineD2, 5-HT2C, histaminic, andmus-
carinic receptors. Any or all of these receptors may be the mediators of
chemotherapy-induced nausea.
Olanzapine also appears to be an effective agent in the treatment of
breakthrough emesis and nausea.
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